Arrowstreet Capital
ANIP icon

Arrowstreet Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Arrowstreet Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.4M Buy
564,360
+91,153
+19% +$7.11M 0.02% 532
2025
Q4 		$37.4M Buy
473,207
+113,029
+31% +$9.79M 0.02% 557
2025
Q3 		$33M Buy
+360,178
New +$29.4M 0.02% 575
2024
Q3 		– Sell
-9,304
Closed -$592K – 1728
2024
Q2 		$592K Buy
9,304
+906
+11% +$58.8K ﹤0.01% 1312
2024
Q1 		$581K Buy
+8,398
New +$507K ﹤0.01% 1428
2022
Q1 		– Sell
-8,538
Closed -$393K – 1178
2021
Q4 		$393K Buy
+8,538
New +$367K ﹤0.01% 1309
2020
Q3 		– Sell
-37,587
Closed -$1.22M – 2312
2020
Q2 		$1.22M Sell
37,587
-55,536
-60% -$1.99M ﹤0.01% 1689
2020
Q1 		$3.79M Sell
93,123
-35,282
-27% -$1.88M 0.01% 840
2019
Q4 		$7.92M Buy
128,405
+122,205
+1,971% +$8.1M 0.02% 686
2019
Q3 		$452K Buy
+6,200
New +$464K ﹤0.01% 1348

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Arrowstreet Capital's ANIP Position: Q1 2026 in Review

Arrowstreet Capital increased its ANI Pharmaceuticals (ANIP) stake by 19% in Q1 2026, buying an estimated $7.11M and bringing the position to 564,360 shares worth $43.4M. The position accounts for 0.02% of the portfolio, ranked #532.

Arrowstreet Capital first reported a position in ANIP in Q3 2019 and has held it in 10 quarters since. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Arrowstreet Capital held 564,360 shares of ANI Pharmaceuticals worth $43.4M as of Q1 2026.
  • Arrowstreet Capital bought 91,153 ANI Pharmaceuticals shares in Q1 2026, an estimated $7.11M.
  • ANI Pharmaceuticals made up 0.02% of Arrowstreet Capital's portfolio in Q1 2026, its #532 holding.
  • Arrowstreet Capital first reported a position in ANI Pharmaceuticals in Q3 2019 and has held it in 10 quarters since.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.